newscancer treatmentchemoradiotherapy
Sustained Locoregional Control With Deintensified Chemoradiotherapy for HPV Oropharyngeal Carcinoma
By MedXY|May 8, 2026
A cohort study demonstrates that reduced-dose 60-Gy chemoradiotherapy effectively maintains locoregional control in HPV-positive oropharyngeal cancer patients while minimizing treatment toxicity, with 5-year survival rates exceeding 92%.
